NantKwest (NK) : Zacks Investment Research ranks NantKwest (NK) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 5 research analysts is 1.4, which indicates as a Strong Buy.
NantKwest (NK) : 4 investment research analysts covering NantKwest (NK) have an average price target of $32.25 for the near short term. The highest target price given by the Brokerage Firm to the stock is $38 and the lowest target is $29 for the short term. Analysts expect the variance to be within $4.03 of the average price.
Shares of NantKwest, Inc. rose by 12.45% in the last five trading days and 28.03% for the last 4 weeks. NantKwest, Inc. is up 12.29% in the last 3-month period. Year-to-Date the stock performance stands at -53.09%. NantKwest (NASDAQ:NK): stock turned positive on Tuesday. Though the stock opened at $7.98, the bulls momentum made the stock top out at $8.52 level for the day. The stock recorded a low of $7.66 and closed the trading day at $8.13, in the green by 3.30%. The total traded volume for the day was 433,253. The stock had closed at $7.87 in the previous days trading.
NantKwest, Inc., formerly Conkwest, Inc., is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases. The Companys product candidates include aNK, haNK and taNK. The Companys aNK product candidates are unmodified aNK cells with natural affinity to stress-induced ligands of diseased cells. The Company develops its aNK product candidates as monotherapies for the treatment of virally-induced cancers, such as polyomavirus induced Merkel cell carcinoma, human Papillomavirus (HPV), induced cervical cancer and head and neck cancer. Its haNK product candidates are aNK cells genetically engineered to express high-affinity CD16, a receptor that allows direct binding of NK cells to antibodies. The Companys taNK product candidate targets specific antigens on the surface of abnormal cells, including CD33, EGFR, HER2/neu, PDL1 and PSMA.